SHINJINEE SENGUPTA

Dr. SHINJINEE SENGUPTA

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2024 in Science Advances
Verified
Journal Article
Open access
DDDebalina Datta
Debalina Datta
ANAmbuja Navalkar
Ambuja Navalkar
ASArunima Sakunthala
Arunima Sakunthala
APAjoy Paul
Ajoy Paul
KPKomal Patel
Komal Patel
SMSamir K Maji
Samir K Maji
Liquid-liquid phase separation of various transcription factors into biomolecular condensates plays an essential role in gene regulation. Here, using cellular models and in vitro studies, we show the spatiotemporal formation and material properties of p53 condensates that might dictate its function. In particular, p53 forms liquid-like condensates in the nucleus of cells, which can bind to DNA and perform transcriptional activity. However, cancer-associated mutations promote misfolding and partially rigidify the p53 condensates with impaired DNA binding ability. Irrespective of wild-type and mutant forms, the partitioning of p53 into cytoplasm leads to the condensate formation, which subsequently undergoes rapid solidification. In vitro studies show that abundant nuclear components such as RNA and nonspecific DNA promote multicomponent phase separation of the p53 core domain and maintain their liquid-like property, whereas specific DNA promotes its dissolution into tetrameric functional p53. This work provides mechanistic insights into how the life cycle and DNA binding properties of p53 might be regulated by phase separation.

1 May 2021 in Journal of Bioscience and Bioengineering
Verified
Journal Article
Open access
VSVaibhav Srivastava
Vaibhav Srivastava
RARuth Amanna
Ruth Amanna
SRStephen J.L. Rowden
Stephen J.L. Rowden
SSSHINJINEE SENGUPTA
SHINJINEE SENGUPTA
SMSwati Madhu
Swati Madhu
PWPramod P. Wangikar
Pramod P. Wangikar
Cyanobacteria hold promise as cell factories for the photoautotrophic conversion of carbon dioxide to useful chemicals. For the eventual commercial viability of such processes, cyanobacteria need to be engineered for (i) efficient channeling of carbon flux toward the product of interest and (ii) improved product tolerance, the latter being the focus of this study. We chose the recently reported, fast-growing, high light and CO2 tolerant cyanobacterium Synechococcus elongatus PCC 11801 for adaptive laboratory evolution. In two parallel experiments that lasted over 8400 h of culturing and 100 serial passages, S. elongatus PCC 11801 was evolved to tolerate 5 g/L n-butanol or 30 g/L 2,3-butanediol representing a 100% improvement in concentrations tolerated. The evolved strains retained alcohol tolerance even after being passaged several times without the alcohol stress suggesting that the changes were permanent. Whole genome sequencing of the n-butanol evolved strains revealed mutations in a number of stress responsive genes encoding translation initiation factors, RpoB and an ABC transporter. In 2,3-butanediol evolved strains, genes for ClpC, a different ABC transporter, glyceraldehyde-3-phosphate dehydrogenase and phosphoribulokinase were found to be mutated. Furthermore, the evolved strains showed significant improvement in tolerance toward several other alcohols. Notably, the n-butanol evolved strain could tolerate up to 32 g/L ethanol, thereby making it a promising host for photosynthetic production of biofuels via metabolic engineering.

25 February 2024 in Cancer Letters
Verified
Journal Article
Closed access
SCShivi Chauhan
Shivi Chauhan
SJShivani Jaiswal
Shivani Jaiswal
VJVibhuti Jakhmola
Vibhuti Jakhmola
BSBhavana Singh
Bhavana Singh
SBSujata Bhattacharya
Sujata Bhattacharya
SSSHINJINEE SENGUPTA
SHINJINEE SENGUPTA

1 September 2023 in Journal of Cell Science
Verified
Journal Article
Closed access
PDF file
SSSHINJINEE SENGUPTA
SHINJINEE SENGUPTA
NSNamrata Singh
Namrata Singh
APAjoy Paul
Ajoy Paul
DDDebalina Datta
Debalina Datta
Debdeep ChatterjeeDebdeep Chatterjee
Debdeep Chatterjee
SMSamir K Maji
Samir K Maji
P53 (also known as TP53) mutation and amyloid formation are long associated with cancer pathogenesis; however, the direct demonstration of the link between p53 amyloid load and cancer progression is lacking. Using multi-disciplinary techniques and 59 tissues (53 oral and stomach cancer tumor tissue samples from Indian individuals with cancer and six non-cancer oral and stomach tissue samples), we showed that p53 amyloid load and cancer grades are highly correlated. Furthermore, next-generation sequencing (NGS) data suggest that not only mutant p53 (e.g. single-nucleotide variants, deletions, and insertions) but wild-type p53 also formed amyloids either in the nucleus (50%) and/or in the cytoplasm in most cancer tissues. Interestingly, in all these cancer tissues, p53 displays a loss of DNA-binding and transcriptional activities, suggesting that the level of amyloid load correlates with the degree of loss and an increase in cancer grades. The p53 amyloids also sequester higher amounts of the related p63 and p73 (also known as TP63 and TP73, respectively) protein in higher-grade tumor tissues. The data suggest p53 misfolding and/or aggregation, and subsequent amyloid formation, lead to loss of the tumor-suppressive function and the gain of oncogenic function, aggravation of which might determine the cancer grade.

26 December 2022 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
SSSHINJINEE SENGUPTA
SHINJINEE SENGUPTA
SGShaikh Maryam Ghufran
Shaikh Maryam Ghufran
AKAqsa Khan
Aqsa Khan
SBSubhrajit Biswas
Subhrajit Biswas
SRSusanta Roychoudhury
Susanta Roychoudhury
The tumor suppressor p53 when undergoes amyloid formation confers several gain-of-function (GOF) activities that affect molecular pathways crucial for tumorigenesis and progression like some of the p53 mutants. Even after successful cancer treatment, metastasis and recurrence can result in poor survival rates. The major cause of recurrence is mainly the remnant cancer cells with stem cell-like properties, which are resistant to any chemotherapy treatment. Several studies have demonstrated the role of p53 mutants in exacerbating cancer stemness properties and epithelial-mesenchymal transition in these remnant cancer cells. Analyzing the amyloid/mutant p53-mediated signaling pathways that trigger metastasis, relapse or chemoresistance may be helpful for the development of novel or improved individualized treatment plans. In this review, we discuss the changes in the metabolic pathways such as mevalonate pathway and different signaling pathways such as TGF-β, PI3K/AKT/mTOR, NF-κB and Wnt due to p53 amyloid formation, or mutation. In addition to this, we have discussed the role of the regulatory microRNAs and lncRNAs linked with the mutant or amyloid p53 in human malignancies. Such changes promote tumor spread, potential recurrence, and stemness. Importantly, this review discusses the cancer therapies that target either mutant or amyloid p53, restore wild-type functions, and exploit the synthetic lethal interactions with mutant p53.

1 June 2025 in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
Verified
Journal Article
Closed access
SJShivani Jaiswal
Shivani Jaiswal
VMVivek Mishra
Vivek Mishra
SMSrija Majumder
Srija Majumder
PWPramod P. Wangikar
Pramod P. Wangikar
SSSHINJINEE SENGUPTA
SHINJINEE SENGUPTA